12 13 CRISPR-Cas systems provide bacteria with adaptive immunity against 14 bacteriophages 1 . However, DNA modification 2,3 , the production of anti-CRISPR 15 proteins 4,5 and potentially other strategies enable phages to evade CRISPR-16 Cas. Here we discovered a Serratia jumbophage that evaded type I CRISPR-17 Cas systems, but was sensitive to type III immunity. Jumbophage infection 18 resulted in a nucleus-like structure enclosed by a proteinaceous phage shell -19 a phenomenon only reported recently for distantly related Pseudomonas 20 phages 6,7 . All three native CRISPR-Cas complexes in Serratia -type I-E, I-F and 21 III-A -were spatially excluded from the phage nucleus and phage DNA was not 22 targeted. However, the type III-A system still arrested jumbophage infection by 23 targeting phage RNA in the cytoplasm in a process requiring Cas7, Cas10 and 24 an accessory nuclease. Type III, but not type I, systems frequently targeted 25 nucleus-forming jumbophages that were identified in global viral sequence 26 datasets. These findings explain why many bacteria harbour both RNA-and 27 DNA-targeting CRISPR-Cas systems 1,8 . Together, our results indicate that 28 jumbophage nucleus-like compartments serve as a barrier to DNA-targeting, 29 but not RNA-targeting defences, and that this phenomenon is widespread 30 amongst jumbophages. 31
1 short repeats and the Cas (CRISPR-associated) proteins that provide the enzymatic 2 machinery for immunity 1 . During phage infection, invading genetic material can be 3 acquired into CRISPR arrays as new spacers 9,10 . Expression and processing of the 4 CRISPR array(s) results in crRNA guides, onto which Cas proteins assemble, 5 forming surveillance complexes 11, 12 . In the interference step, recognition of foreign 6 genetic material complementary to the crRNA leads to degradation of the phage 7 nucleic acids and infection is arrested 13 . CRISPR-Cas systems are classified into two 8 classes and six different types and bacteria often harbour multiple systems 8 . For 9 example, Serratia sp. ATCC 39006 encodes three systems -type I-E and I-F that 10 target DNA and type III-A that targets DNA and RNA 14 . 11
To identify new CRISPR-Cas evasion mechanisms, we isolated phages infecting 12
Serratia and assessed their sensitivity to CRISPR-Cas immunity. Of these phages, a 13 member of the Myoviridae family was selected for further characterisation and 14 named PCH45 ( Figure 1A ). PCH45 has a circularly permuted double-stranded DNA 15 genome of 212,807 kb and is therefore a jumbophage (i.e. phages with genomes 16 >200kb; Figure 1B ) 15 . Sequence analysis of individual genes or the complete 17 genome revealed that PCH45 is highly divergent from known jumbophages, 18
including the well characterised Pseudomonas Phikzviruses ( Figure 1C ) 16, 17 . Indeed, 19
its closest relatives, Erwinia phage PhiEaH1 and Serratia phage 2050HW, showed 20 little sequence conservation ( Figure S1 ). In summary, we identified a unique phage 21 distinct from other described jumbophages. lengths are scaled according to the distance formula (d6). D. Major capsid gene (gp033) targets of 7 chromosomal type I-E (S1), I-F (S2) and III-A (S3) spacers. Phage resistance by E. efficiency of 8 plaquing (EOP) or F. plate reader assays for strains with no (WT; control), type I-E (S1, PCF592) or I-9 F (S2, PCF574) spacers. G. Conjugation efficiency of untargeted (pPF1123) and targeted (gp033, 
16
To test if the Serratia type I CRISPR-Cas systems elicit jumbophage resistance, we 17 generated strains with chromosomal anti-gp033 (major capsid) spacers in CRISPR1 18 (I-E) and CRISPR2 (I-F) ( Figure 1D , S2A and Table S4 ). These anti-PCH45 spacers 19
failed to provide jumbophage resistance on plate or liquid cultures ( Figure 1E&F , 20 S2B), despite interfering strongly with plasmids (10 5 fold reduction in conjugation) 21 ( Figure 1G ). Importantly, these Serratia type I systems provide resistance against 22 other phages, including Siphovirus JS26 18 . The jumbophage appeared to avoid type 1 I immunity in an anti-CRISPR-independent manner, since no known acr genes were 2 detected in the PCH45 genome. Furthermore, the jumbophage DNA was sensitive to 3 digestion by restriction enzymes and no genes encoding known DNA modification 4 enzymes were detected in the genome, indicating that DNA modification was not 5 obstructing CRISPR-Cas defence ( Figure S2E ). It was also possible that CRISPR-6
Cas expression was insufficient in Serratia to provide resistance; however, the 7 jumbophage still evaded type I immunity when crRNAs were overexpressed from 8 mini-CRISPR arrays ( Figure 1H -J and S2C-D). We next examined type III immunity 9 by expressing a spacer targeting the jumbophage major capsid mRNA. In contrast to 10 the type I systems, the type III-A system provided robust phage resistance ( Figure  11 1K&L). Thus, the type III-A system protected against the Serratia jumbophage, 12
whereas the type I systems were evaded in an unknown process. 13
We were interested in how the jumbophage evaded type I, yet was susceptible to 14 type III immunity. Recently, three Pseudomonas Phikzvirus phages were shown to 15 produce nucleus-like structures during infection 6, 7 . The phage nucleus is surrounded 16 by a shell of phage proteins and is positioned in the cell centre by a phage-encoded 17 tubulin spindle (PhuZ) 7, 19, 20 . The Serratia jumbophage, despite bearing little similarity 18 to the Phikzvirus genus, encodes a tubulin homologue (gp187) and a potential shell 19 protein (gp202) ( Figure 1B ). These proteins have low sequence identity (16.5% and 20
19.9% at the amino acid level for PhuZ and the shell protein, respectively) to those in 21 the Pseudomonas phage phiKZ (type species of the Phikzvirus genus) ( Figure  22 S3A&B). Therefore, we hypothesised the Serratia jumbophage produces a nucleus-23 like compartment upon infection. Serratia was infected with PCH45 and confocal 24 microscopy was used to visualise DNA and membranes. During infection we 25 observed circular DNA foci, consistent with nucleus-like structures (Figure 2A ). By 26 contrast, DNA was evenly distributed in uninfected controls. Thirty minutes after 27 infection, most phage nuclei were either localised centrally (n=102; 61%), or towards 28 the cell poles (n=64; 39%). To test if the DNA foci were encapsulated by a phage 29 shell, the putative shell protein was tagged (mEGFP-gp202). Upon phage infection, 30 the tagged shell protein assembled into a spherical structure enclosing the phage 31 DNA but no shell was formed without infection ( Figure 2B ). Therefore, phage 32 infection leads to DNA accumulation within a phage-encoded protein shell that 1 includes protein Gp202. 14 In Pseudomonas Phikzvirus 201 Φ2-1, shell formation allows the selective 15 translocation of proteins into the phage nucleus, restricting other proteins to the 16 cytoplasm 6 . We hypothesised that the Serratia jumbophage evades DNA targeting 17 due to the nucleus-like compartment excluding Cas proteins from phage DNA. 18 Therefore, we monitored CRISPR-Cas interference complex localisation during 19 jumbophage infection with the large subunit of all systems tagged with mCherry (I-E, 20 cas8e; I-F, cas8f; and III-A, cas10). All tagged systems retained interference activity 1 against the CRISPR-sensitive phage JS26 ( Figure S3C ). For all CRISPR-Cas types, 2 the interference complexes were localised in the cytoplasm external to the phage 3 nucleus ( Figure 2C ). Together, this shows that the CRISPR-Cas complexes are 4 spatially excluded from the phage nucleus, preventing access to the phage DNA. 5
Replication and transcription of Phikzvirus DNA occurs inside the nucleus-like 6 compartment and mRNA is transported to the cytoplasm for translation 6 . This is 7 consistent with the Serratia jumbophage being protected from type I systems (target 8 DNA), while remaining sensitive to type III (targets both RNA and DNA) 21,22 . To 9 further investigate the role of type III RNA targeting in jumbophage defence, we 10 tested a panel of crRNAs that target different PCH45 genes ( Figure 3A) . In the Cas10 Palm domain, which synthesises cyclic oligoadenylate secondary 20 messengers that activate non-specific RNases, causing collateral RNA 21 degradation [25] [26] [27] . The Serratia type III-A system has two CRISPR-arrays (CRISPR3 22 and CRISPR4), an operon encoding the adaptation complex and an operon 23 encoding the Csm complex ( Figure 3E ). In addition, a hypothetical nuclease is 24 convergently transcribed between cas6 and CRISPR4. To investigate RNA targeting 25 by the Serratia type III-A system in the inhibition of jumbophage infection, catalytic 26 mutants of the key proteins involved in RNA and DNA cleavage were tested with 27 multiple spacers ( Figure 3F&G and S4A) . As predicted, a Cas10 HD mutation 28 (cas10 H17A, N18A ) did not affect type III-A immunity, indicating that DNA cleavage is 29 not necessary for jumbophage resistance. In contrast, active site mutations in Cas7 30 (aka Csm3; csm3 D34A ) 23 or the Cas10 Palm domain (cas10 D618A, D619A ), which disrupts 31 cyclic oligoadenylate signalling 26 , abolished phage resistance. Moreover, resistance 32 was also lost when the accessory nuclease was deleted. The same effects on 1 interference of plasmid conjugation were observed for all mutants and restoration of 2 the WT copy of each mutant gene complemented CRISPR-Cas activity ( Figure S4B 7 phage genome indicating targets of the type III-A spacers: major capsid (gp033; S3 and S13), RNA-8 polymerase beta subunit (gp084; S9), terminase large subunit (gp159; S10 and S14), tubulin-like 9 protein (gp187; S11 and S15) and helicase (gp217; S12). B. EOP assay for strains expressing type 10 III-A spacers from mini-CRISPR arrays (Control; pPF975, S3; pPF1467, S9; pPF1466, S10; pPF1469, 11 S11; pPF1470 and S12; pPF1468). Plate reader assay of strains expressing the spacers in B. either 
17
We hypothesised that type III CRISPR-Cas immunity against nucleus-forming 18 jumbophages would occur in natural environments, whereas type I immunity would 19 be rare. To test this hypothesis, we analysed type I-E, I-F and III spacers from 20 ~160,000 bacterial genomes and identified their targets in isolated phage genomes 21 and viral contigs from global metagenomes (Table S2) . For total phages, many 1 targets were identified for all systems ( Figure 4A) . Consistent with our model, targets 2 of type III spacers were significantly enriched in jumbophages (i.e. >200 kb) ( Figure  3 4A&B) and further enriched in nucleus-forming phages that encode homologues of 4 both shell and tubulin proteins (c 2 test <0.001) ( Figure 4C) . Multiple examples of type 5 III systems targeting nucleus-forming jumbophages were present in diverse classes 6 of proteobacteria. In contrast, type I-E and I-F spacer matches were depleted in 7 jumbophages and those defined as nucleus-forming ( Figure 4B&C and S4E) . In 8 conclusion, both experimental and bioinformatic data provide evidence that type III 9 CRISPR-Cas immunity against jumbophages is widespread in nature, but that these 10 phages evade type I immunity. 
16
We have discovered a jumbophage that evades DNA targeting by two native type I 17 CRISPR-Cas systems while retaining sensitivity to the RNA targeting capabilities of 18 the type III-A system. We propose that resistance is conferred by the formation of a 19 nucleus-like structure in the bacterial cytoplasm that physically shields DNA, but not 20 RNA, from cytoplasmic CRISPR-Cas effector complexes. This concept of exclusion-21 defence was proposed earlier for Phikzviruses 7 and is supported by a recent 22
unpublished study showing phage DNA, but not RNA, is protected from immune 23 systems different to those tested in this study 28 . Our work on a unique jumbophage 24 that infects a different order of bacteria, and bears little similarity to the Phikzvirus 25 genus, coupled with our bioinformatic analyses, provides evidence that the phage 26 nucleus is a widespread counter-defence strategy amongst jumbophages. This 27 manner of immune evasion leads to the prediction that the phage nucleus would 28 provide broad protection from diverse DNA-targeting defence systems. This quality 29 makes nucleus-forming phages prime candidates for phage-based therapies. 1 Importantly, despite DNA protection, RNA export to the cytoplasm is a vulnerability of 2 jumbophages that can be exploited by type III CRISPR-Cas systems. It is likely that 3 jumbophage infection has selected for the observed widespread type III RNA-4 targeting immunity in strains already possessing DNA-based defences. 5
Methods 6
Detailed Methods are provided in the Supplementary Information. 7
